ReportsandReports : The Gastrointestinal Market Outlook to 2014: Market Dynamics, Competitive Landscape, Emerging Therapies
DALLAS, March 2, 2010 /PRNewswire/ -- ReportsandReports announce to have The Gastrointestinal Market Outlook to 2014: ( http://www.reportsandreports.com/market-reports/the-gastrointestinal-market-o utlook-to-2014-market-dynamics-com/) Market dynamics, competitive landscape, emerging therapies Market Research Report in its store.
(Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)
Gastrointestinal disorders are quite diverse affecting different parts of the alimentary tract such as the pancreas, oropharynx, liver and biliary system and the alimentary canal. Causes of these disorders vary and could include genetic anomalies, the effect of certain toxins and drugs, infections, cancer and often unknown causes. Disorders of the gastrointestinal tract (GIT) are fairly common and occur in people of all ages. These disorders take up a significant share of the disease burden in developed economies and the gravity of the problem is further accentuated by the difficulty that they pose in effective management. GIT therapy area consists of some indications that can be treated through pharmacologic interventions, though significant unmet need still exists. These unmet medical needs are more common for indications such as irritable bowel syndrome (IBS), Crohn's disease (CD) and ulcerative colitis (UC). An incomplete understanding of the etiologies of these diseases limits their effective treatment, leading to misguided treatment and misdiagnosis. A significant fraction of the drugs used in the GIT therapy area are for the treatment of peptic ulcer disease (PUD) and gastroesophageal reflux disease (GERD). The therapy area overall, however, reflects significant levels of genericization with R&D efforts drifting towards novel therapies for Crohn's disease and inflammatory bowel disease (IBD). In several instances though, the shift could be out of GIT to the faster growing therapy areas such as oncology, cardiovascular disorders and autoimmune disorders.
Scope of this report
- Epidemiological analysis of the therapy area and forecast prevalence
over the period 2009-14
- Forecasts and analysis of the key products in the gastrointestinal
market over the period 2009-14 across major classes of treatments
- Detailed analysis across major classes of gastrointestinal treatment
including immunosuppressants and anti-rheumatic agents
- Detailed analysis of the clinically differentiated products in the
gastrointestinal market pipeline and sales forecast of key R&D pipeline
products in the global gastrointestinal market
Key findings from this report
Growth in the Crohn's disease and ulcerative colitis market is likely to be driven by self-injectable products. This would lead to the transition of a significant proportion of patients on Remicade therapy to these products. The convenience of self-injection would help in driving growth in this category while facilitating earlier use of drugs. These dynamics have the potential to fuel growth while expanding the market in these categories.
AstraZeneca has constituted a new company, which will be funded by three private equity firms, with several of its gastrointestinal programs. This new biotech venture of the company, called Albireo, has taken up one early stage clinical program, besides some preclinical programs of the company. The private equity firms involved are - TVM Capital, Phase4 Ventures and Scottish Widows Investment Partnership. This new venture of AstraZeneca is a bid towards streamlining its gastrointestinal development projects in key indications such as GERD and for line extensions of its market leading product Nexium.
Many of the top ten players posted a decline in sales over 2007, a fact indicative of the high degree of genericization in the market. Over all, drugs indicated for the treatment of ulcer are expected to drag down the sales of most players. Thus, companies that have maintained a more diverse drug class portfolio are expected to gain more in the long run.
Use this report to:
- Develop insights into patient potential with the report's coverage of
the therapy area and top ten leading gastrointestinal players today.
- Quickly understand how recent events are affecting the performance of
major products, and how leading players are confronting competitive
challenges in the gastrointestinal marketplace.
- Gain up-to-date market intelligence across the gastrointestinal
category and understand the major issues affecting key pharmaceutical
marketers.
- Understand which drug classes have the greatest potential to drive
gastrointestinal franchise growth, and how pharmaceutical companies are
attempting to capitalize these market opportunities.
- Compare the franchises of leading pharmaceutical companies across key
therapeutic classes and understand how market share of leading
companies will evolve over the next six years.
Related Reports
- Abbott Laboratories-Deals & Alliances Report
- Abbott Laboratories-Detailed Product Pipeline
- Abbott Laboratories-IT Sales Opportunities-2009
- Abbott Laboratories: PharmaVitae Profile
- Acorda Therapeutics, Inc.-Deals & Alliances Report
About Us
ReportsandReports, (http://www.reportsandreports.com/) comprising of an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts of almost all well-known publishers of such reports across the globe. We, as a third party reseller of market research reports employ number of marketing tools such as press releases, email-marketing and effective search engine optimization technique to drive revenues for our clients. We also provide 24/7 online and offline support to our customers.
Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
Email: [email protected]
http://www.reportsandreports.com/
SOURCE MarketsandMarkets
Share this article